Abstract
Markers of the inflammatory response, interleukin 6, C-reactive protein, albumin and full blood count, were measured in non-small-cell lung cancer (NSCLC) patients (n = 21) with and without weight loss ( > 5%). There were significant increases in circulating C-reactive protein (P < 0.001), interleukin 6 (P < 0.01) and platelets (P < 0.01) in the weight-losing group. Moreover, there was a statistically significant correlation (r = 0.785, P < 0.001) between interleukin 6 and C-reactive protein concentrations. These results are consistent with interleukin 6 and the acute phase response promoting weight loss in NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, H., McMillan, D., Crilly, A. et al. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 73, 1560–1562 (1996). https://doi.org/10.1038/bjc.1996.294
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.294
This article is cited by
-
Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients
European Journal of Clinical Pharmacology (2022)
-
Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma
Oncogene (2017)
-
Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling
Scientific Reports (2017)
-
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?
BMC Cancer (2016)
-
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia
Oncogene (2016)